Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Alzheimer's disease (AD) is a major healthcare challenge with no curative treatment at
present. To address this challenge, we need a paradigm shift, where we focus on pre …

A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …

Background Development of in vivo biomarkers has shifted the diagnosis of Alzheimer's
disease (AD) from the later dementia stages of disease towards the earlier stages and has …

Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease
(AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

For decades, the hypothesis that brain deposition of the amyloid β protein initiates
Alzheimer's disease has dominated research and clinical trials. Targeting amyloid β is …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Importance Longitudinal tau positron emission tomography (PET) is a relevant outcome in
clinical trials evaluating disease-modifying therapies in Alzheimer disease (AD). A key …

The ATN framework proposes a shift from a syndrome to a biological construct of Alzheimer
disease (AD) for research purposes. 1 According to this framework, whereAstands for …